A patient with cancer should always anticipate a positive response; however, he should be aware of the correct facts. Thus, what does a patient diagnosed with triple-negative breast cancer (TNBC) think and perceive? Similar to many oncologists, the word “triple-negative” brings a mental picture of, “A disease that will be difficult to treat, relapse early, and have a very short survival when relapsed.” Although this assumption is challenging for the doctor, it is particularly terrifying for the patient. Furthermore, the effect of emotional state on survival is a well-established fact.1
{"title":"There are Two Ways of Spreading Light: To Be the Candle or the Mirror That Reflects It","authors":"E. Almuradova","doi":"10.37047/jos.2021-83165","DOIUrl":"https://doi.org/10.37047/jos.2021-83165","url":null,"abstract":"A patient with cancer should always anticipate a positive response; however, he should be aware of the correct facts. Thus, what does a patient diagnosed with triple-negative breast cancer (TNBC) think and perceive? Similar to many oncologists, the word “triple-negative” brings a mental picture of, “A disease that will be difficult to treat, relapse early, and have a very short survival when relapsed.” Although this assumption is challenging for the doctor, it is particularly terrifying for the patient. Furthermore, the effect of emotional state on survival is a well-established fact.1","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69820350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gökhan Vatansever, Tarık Keçeli̇, Önder Kırca, A. Basarir, M. Özdoğan
creased over the past decades.1 This has, in turn, substantially increased the amount of effort required to address the side effects of cancer therapies. Healthcare professionals should proactively adopt strategies to improve the quality of life of cancer survivors and maximize their reintegration into the community and daily work routine after recovery from cancer. A significant challenge that might decelerate or prevent the social rehabilitation of cancer survivors is cancer-induced cognitive impairment, also colloquially known as “chemobrain” or “chemofog.” It has been reported that 10-40% of all cancer patients suffer from cancerinduced cognitive impairment.2 Most importantly, several cancer patients with this complication eventually quit or change their professions; around 30% fail in their previous positions within two years after cancer therapy.3,4 Cancer-induced cognitive impairment can be associated with the disease and its treatments such as chemotherapy, radiotherapy, hormone therapy, and novel anticancer treatments.5-9
{"title":"Gamification as a Solution for Cancer-Induced Cognitive Impairment","authors":"Gökhan Vatansever, Tarık Keçeli̇, Önder Kırca, A. Basarir, M. Özdoğan","doi":"10.37047/jos.2020-78809","DOIUrl":"https://doi.org/10.37047/jos.2020-78809","url":null,"abstract":"creased over the past decades.1 This has, in turn, substantially increased the amount of effort required to address the side effects of cancer therapies. Healthcare professionals should proactively adopt strategies to improve the quality of life of cancer survivors and maximize their reintegration into the community and daily work routine after recovery from cancer. A significant challenge that might decelerate or prevent the social rehabilitation of cancer survivors is cancer-induced cognitive impairment, also colloquially known as “chemobrain” or “chemofog.” It has been reported that 10-40% of all cancer patients suffer from cancerinduced cognitive impairment.2 Most importantly, several cancer patients with this complication eventually quit or change their professions; around 30% fail in their previous positions within two years after cancer therapy.3,4 Cancer-induced cognitive impairment can be associated with the disease and its treatments such as chemotherapy, radiotherapy, hormone therapy, and novel anticancer treatments.5-9","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Şimşek, D. Güven, F. Ceylan, I. Y. Cakir, T. K. Şahin, Ö. Dizdar, Y. Balaban, Ş. Yalçın
115 Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease even in the localized stage. The 5-year survival is approximately 10% in the USA, and 8085% of the patients present unresectable or metastatic cancer.1,2 Even for individuals eligible for surgery, the prognosis is dismal, with only 20% surviving 5 years.1-3 While recent advances in surgery and adjuvant chemotherapy have improved survival times, the outcomes are still far from desired. PDAC remains the fourth leading cause of cancer-related deaths in the world.4 A significant obstacle is the considerable heterogeneity of the disease and the lack of reliable clinical risk stratification. Early-stage colorectal cancer and breast cancer do not present these disadvantages, and hence, it is easy to tailor treatment selection. In the constantly changing paradigm of new treatments, it is essential to identify prediction strategies for selecting the best treatment for the right patient.5 However, current knowledge currently lacks such guiding ability.
{"title":"Machine Learning Models Predict Early Postoperative Relapse in Pancreatic Cancer","authors":"C. Şimşek, D. Güven, F. Ceylan, I. Y. Cakir, T. K. Şahin, Ö. Dizdar, Y. Balaban, Ş. Yalçın","doi":"10.37047/jos.2021-84326","DOIUrl":"https://doi.org/10.37047/jos.2021-84326","url":null,"abstract":"115 Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease even in the localized stage. The 5-year survival is approximately 10% in the USA, and 8085% of the patients present unresectable or metastatic cancer.1,2 Even for individuals eligible for surgery, the prognosis is dismal, with only 20% surviving 5 years.1-3 While recent advances in surgery and adjuvant chemotherapy have improved survival times, the outcomes are still far from desired. PDAC remains the fourth leading cause of cancer-related deaths in the world.4 A significant obstacle is the considerable heterogeneity of the disease and the lack of reliable clinical risk stratification. Early-stage colorectal cancer and breast cancer do not present these disadvantages, and hence, it is easy to tailor treatment selection. In the constantly changing paradigm of new treatments, it is essential to identify prediction strategies for selecting the best treatment for the right patient.5 However, current knowledge currently lacks such guiding ability.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69820726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Cil, Abdilkerim Oyman, S. Isik, M. Ayhan, I. Ökten, Mustafa YILMAZ, Melike Özçelik
125 Biliary tract cancers (BTC) are a group of malignant tumors originating from the bile duct epithelium and include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder carcinoma (GBC).1,2 They constitute 0.7% of all cancers and 3% of all gastrointestinal cancers; approximately 250,000 new patients were diagnosed in 2020.3-5 Unfortunately,70% of BTCs are unresectable at the time of diagnosis, and their 5-year survival rate ranges from 5% to 15%.6,7 Although surgery being the only definitive treatment, R0 resection is possible in only 70% of patients. Moreover, the median overall survival (OS) duration of operated patients is less than 5 years despite the usage of modern surgical methods and adjuvant therapies.8
{"title":"Prognostic Factors in Resected Biliary Tract Cancers and the Impact of Cytokeratin 20 Expression","authors":"I. Cil, Abdilkerim Oyman, S. Isik, M. Ayhan, I. Ökten, Mustafa YILMAZ, Melike Özçelik","doi":"10.37047/jos.2021-84414","DOIUrl":"https://doi.org/10.37047/jos.2021-84414","url":null,"abstract":"125 Biliary tract cancers (BTC) are a group of malignant tumors originating from the bile duct epithelium and include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder carcinoma (GBC).1,2 They constitute 0.7% of all cancers and 3% of all gastrointestinal cancers; approximately 250,000 new patients were diagnosed in 2020.3-5 Unfortunately,70% of BTCs are unresectable at the time of diagnosis, and their 5-year survival rate ranges from 5% to 15%.6,7 Although surgery being the only definitive treatment, R0 resection is possible in only 70% of patients. Moreover, the median overall survival (OS) duration of operated patients is less than 5 years despite the usage of modern surgical methods and adjuvant therapies.8","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Prognostic Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured by 18F-FDG PET/CT in Patients with NSCLC","authors":"S. Göksel, A. Cengiz, H. Öztürk, Y. Yürekli","doi":"10.37047/jos.2021-86651","DOIUrl":"https://doi.org/10.37047/jos.2021-86651","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
50 Despite advancements in oncological treatments, anthracyclines still form the basis of the treatment. Anthracycline chemotherapy plays a prominent role in treating many forms of cancer. Unfortunately, the dose-dependent and cumulative cardiotoxicity limit the use of anthracyclines.1 Cardiotoxic side effects limit their dosing, and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The exact mechanism of anthracycline-induced cardiotoxicity is still unclear, although it is likely to be multifactorial. The primary mechanism of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase II, and other indirect pathways. Application of various strategies can minimize anthracycline-induced cardiotoxicity; one such method is dexrazoxane, a cardioprotective agent. Dexrazoxane has been used in cancer patients to prevent anthracycline-related cardiotoxicity since the 1980s. Dexrazoxane, an ethylene diamine tetraacetic acid, such as Evaluation of Demographic Parameters, Disease Burden, and Cardiovascular Risk Factors in Patients Who Received Primary Prophylaxis with Dexrazoxane for Prevention of Anthracycline-Induced Cardiotoxicity
{"title":"Evaluation of Demographic Parameters, Disease Burden, and Cardiovascular Risk Factors in Patients Who Received Primary Prophylaxis with Dexrazoxane for Prevention of Anthracycline-Induced Cardiotoxicity","authors":"Gülhan İPEK DENİZ, Ş. Gündüz","doi":"10.37047/jos.2020-80963","DOIUrl":"https://doi.org/10.37047/jos.2020-80963","url":null,"abstract":"50 Despite advancements in oncological treatments, anthracyclines still form the basis of the treatment. Anthracycline chemotherapy plays a prominent role in treating many forms of cancer. Unfortunately, the dose-dependent and cumulative cardiotoxicity limit the use of anthracyclines.1 Cardiotoxic side effects limit their dosing, and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The exact mechanism of anthracycline-induced cardiotoxicity is still unclear, although it is likely to be multifactorial. The primary mechanism of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase II, and other indirect pathways. Application of various strategies can minimize anthracycline-induced cardiotoxicity; one such method is dexrazoxane, a cardioprotective agent. Dexrazoxane has been used in cancer patients to prevent anthracycline-related cardiotoxicity since the 1980s. Dexrazoxane, an ethylene diamine tetraacetic acid, such as Evaluation of Demographic Parameters, Disease Burden, and Cardiovascular Risk Factors in Patients Who Received Primary Prophylaxis with Dexrazoxane for Prevention of Anthracycline-Induced Cardiotoxicity","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Sümbül, Ş. Yalçın, A. Özet, S. Ünal, O. Dizdar, H. Akbulut, A. Karaoglu, N. Karadurmuş, M. Şendur, E. Çılbır, F. Yıldız, G. Tufan, O. Sonmez, N. Turhal
{"title":"Turkish Society of Medical Oncology COVID-19 Pandemic Advisory Board Updated Recommendations for Medical Oncologists: Included Vaccination","authors":"A. Sümbül, Ş. Yalçın, A. Özet, S. Ünal, O. Dizdar, H. Akbulut, A. Karaoglu, N. Karadurmuş, M. Şendur, E. Çılbır, F. Yıldız, G. Tufan, O. Sonmez, N. Turhal","doi":"10.37047/JOS.2021-81962","DOIUrl":"https://doi.org/10.37047/JOS.2021-81962","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"7 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Demircan, T. Akın Telli, Tuğba Başoğlu, R. Arıkan, Alper Yaşar, A. Celebı, Özkan Alan, S. Isik, Özlem Ercelep, F. Dane, P. Yumuk
gland is adrenocortical carcinoma (ACC). ACC is a highly rare malignancy, with an incidence of 0.7-2 per million population.1 Although a diagnosis can be made at any age, ACC more frequently affects women, and its incidence peaks in the fourth to fifth decades of life.2 ACCs are generally sporadic; however, they are occasionally observed as a component of hereditary syndromes like Li-Fraumeni or Beckwith-Wiedemann syndrome.3 Approximately 60% of patients present with symptoms owing to adrenal hormone secretion, where cortisol excess (Cushing syndrome) is the leading manifestation followed by secretion of sex hormones (primarily androgen).1,4 Non-functional ACCs cause symptoms owing to tumor burden, particularly abdominal pain and weight loss. Most ACC cases are diagnosed at an advanced stage, and 5-year survival remains below 50%.5
{"title":"Clinicopathological Features, Treatment Outcomes, and Prognostic Factors in Adrenocortical Carcinoma: A Single-Center Experience","authors":"N. Demircan, T. Akın Telli, Tuğba Başoğlu, R. Arıkan, Alper Yaşar, A. Celebı, Özkan Alan, S. Isik, Özlem Ercelep, F. Dane, P. Yumuk","doi":"10.37047/jos.2021-84514","DOIUrl":"https://doi.org/10.37047/jos.2021-84514","url":null,"abstract":"gland is adrenocortical carcinoma (ACC). ACC is a highly rare malignancy, with an incidence of 0.7-2 per million population.1 Although a diagnosis can be made at any age, ACC more frequently affects women, and its incidence peaks in the fourth to fifth decades of life.2 ACCs are generally sporadic; however, they are occasionally observed as a component of hereditary syndromes like Li-Fraumeni or Beckwith-Wiedemann syndrome.3 Approximately 60% of patients present with symptoms owing to adrenal hormone secretion, where cortisol excess (Cushing syndrome) is the leading manifestation followed by secretion of sex hormones (primarily androgen).1,4 Non-functional ACCs cause symptoms owing to tumor burden, particularly abdominal pain and weight loss. Most ACC cases are diagnosed at an advanced stage, and 5-year survival remains below 50%.5","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Ak, N. Paksoy, M. Velidedeoğlu, Z. Turna, F. Demi̇relli̇
42 Neoadjuvant chemotherapy (NAC) could eliminate existing potential micrometastases and prevent the growth of occult micrometastases that originated from released tumor cells during surgery, and also allowed breast-conserving at higher rates.1 Though the main expected benefit of treatment modalities is to improve disease-free survival (DFS) and progressionfree survival, investigators are trying to translate therapeutic results into better survival rates. It is critical to avoid under-treatment or overtreatment, despite a lack of clarity in determining the extent of the therapy and aiming for the best survival results. Breast cancer has been staged using the American Joint Committee on Cancer (AJCC) Tumor, Node, and Metastasis (TNM) staging system since the first edition in 1977.2 There are different neoadjuvant response evaluation systems, and “MillerPayne Criteria” is accepted useful in various cancer centers; it is graded from 1 to 5; because the pathological examination has decision-making importance and has not been standardized yet.3 Also, the clinical course of patients with pathologic complete response (pCR) remains unclear due to conflicting results. Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer
{"title":"Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer","authors":"N. Ak, N. Paksoy, M. Velidedeoğlu, Z. Turna, F. Demi̇relli̇","doi":"10.37047/jos.2020-79256","DOIUrl":"https://doi.org/10.37047/jos.2020-79256","url":null,"abstract":"42 Neoadjuvant chemotherapy (NAC) could eliminate existing potential micrometastases and prevent the growth of occult micrometastases that originated from released tumor cells during surgery, and also allowed breast-conserving at higher rates.1 Though the main expected benefit of treatment modalities is to improve disease-free survival (DFS) and progressionfree survival, investigators are trying to translate therapeutic results into better survival rates. It is critical to avoid under-treatment or overtreatment, despite a lack of clarity in determining the extent of the therapy and aiming for the best survival results. Breast cancer has been staged using the American Joint Committee on Cancer (AJCC) Tumor, Node, and Metastasis (TNM) staging system since the first edition in 1977.2 There are different neoadjuvant response evaluation systems, and “MillerPayne Criteria” is accepted useful in various cancer centers; it is graded from 1 to 5; because the pathological examination has decision-making importance and has not been standardized yet.3 Also, the clinical course of patients with pathologic complete response (pCR) remains unclear due to conflicting results. Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：